2 recruiting, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow Pleural Mesotheliomas: new trials by email Literature Review of Pleural Mesotheliomas trials Research Report on Pleural Mesotheliomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Cemiplimab, Fianlimab, Pemetrexed (Alimta) - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 126 | 2026-04-02 | 2026-08-11 |
| Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy Ivonescimab - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 38 | 2025-06-30 | 2026-08-10 |
| Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies Decitabine, Depsipeptide, Celecoxib - Advanced Esophageal Cancers, Primary Small Cell Lung Cancers | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2002-05-17 | 2019-09-30 |
Mesothelioma, Malignant (3) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Adenoma (3) · Lung Diseases (3) · Mesothelioma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Mesothelial (3) · Pleural Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Lung Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Carboplatin (1) · Celecoxib (1) · Cisplatin (1) · Decitabine (1) · Depsipeptides (1) · Pemetrexed (1) · cemiplimab (1)
Intergroupe Francophone de Cancerologie Thoracique (2) · National Cancer Institute (NCI) (1)
France (2) · United States (1)